Business, energy, technology, markets and global industry news from Business News Today

Eli Lilly and Company

PharmaDeviceNews Eli Lilly and Company
Representative image of ovarian cancer research and drug development. Eli Lilly’s sofetabart mipitecan has received FDA Breakthrough Therapy designation for platinum-resistant ovarian cancer, signaling progress in FRα-targeted therapies.
Pharma & Biotech

Lilly’s sofetabart mipitecan gets FDA Breakthrough Therapy designation for ovarian cancer

Eli Lilly and Company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for its investigational antibody-drug conjugate, sofetabart mipitecan, also known as LY4170156. The designation applies to adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received prior treatment with bevacizumab and mirvetuximab soravtansine. The novel

Read More
Representative image of an AI-powered drug discovery lab, showcasing robotics, molecular modeling, and digital twin simulations—core elements of the NVIDIA and Eli Lilly co-innovation initiative to transform pharmaceutical R&D.
Pharma & Biotech

Lilly and NVIDIA commit $1bn to AI co-innovation lab for next-gen drug discovery

Eli Lilly and Company and NVIDIA have announced the formation of a co-innovation lab aimed at accelerating drug discovery using AI, robotics, and advanced compute. With a planned $1 billion investment over five years, the lab will leverage NVIDIA’s BioNeMo platform and Vera Rubin architecture alongside Lilly’s drug development expertise. The initiative represents one of

Read More
A representative image of advanced single-cell analysis and AI-driven drug discovery workflows, reflecting Illumina’s Billion Cell Atlas initiative with AstraZeneca, Merck, and Eli Lilly to accelerate next-generation precision medicine.
Medical Devices & Diagnostics

Illumina’s Billion Cell Atlas marks inflection point for AI-enabled drug discovery in 2026

Illumina, Inc. has launched the Billion Cell Atlas, a large-scale genetic perturbation dataset designed to serve as foundational infrastructure for artificial intelligence-enabled drug discovery. Announced alongside strategic collaborations with AstraZeneca, Merck, and Eli Lilly and Company, the platform leverages CRISPR-based genome editing and single-cell RNA sequencing across more than 200 disease-relevant cell lines. This marks

Read More
Pharma & Biotech

Aktis Oncology raises $318m IPO: What this means for alpha radiotherapy biotech bets

Can Aktis Oncology’s IPO jumpstart alpha radiopharma? Find out what its $318M raise means for solid tumor treatment and VC-to-IPO biotech strategy.

Read More
Pharma & Biotech

Why Revvity’s Signals Xynthetica integration with Lilly TuneLab could reshape biotech AI

Revvity and Lilly team up to scale AI-powered drug discovery. Find out how federated learning could reshape access to predictive models across biotech.

Read More
Pharma & Biotech

Eli Lilly taps Chai Discovery to accelerate biologics with AI-generated candidates

Eli Lilly partners with Chai Discovery to deploy AI for antibody drug design. Find out what this means for the future of biologics R&D.

Read More
Pharma & Biotech

Ventyx to give Lilly an oral inflammation pipeline—what’s the real upside?

Eli Lilly and Company has announced plans to acquire Ventyx Biosciences Inc. in an all-cash transaction valued at approximately $1.2 billion, securing a portfolio of clinical-stage oral small molecule therapeutics focused on chronic inflammatory-mediated diseases. The deal includes NLRP3 inhibitors such as VTX2735 and VTX3232, alongside two Phase 2 programs for inflammatory bowel disease. The

Read More
Pharma & Biotech

Can a global trials map help fix spondyloarthritis’s fragmented development landscape?

Explore what global spondyloarthritis trial trends in 2025 reveal about innovation gaps, sponsor risk, and regulatory hurdles. Read the full industry analysis.

Read More
Representative image showing oral weight loss medication with a measuring tape and water glass in the background, illustrating the growing shift from injectable GLP-1 therapies to convenient, daily oral treatments like orforglipron.
Features & Analysis

Can oral GLP-1s maintain weight loss after injectables? Lilly’s orforglipron may prove it can

Eli Lilly and Company (Lilly) has reported positive topline results from the ATTAIN-MAINTAIN Phase 3 trial evaluating orforglipron, its once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, for maintenance of weight loss in patients previously treated with injectable incretins. The trial enrolled participants who had completed 72 weeks of treatment with semaglutide (Wegovy) or tirzepatide (Zepbound)

Read More
Pharma & Biotech

Why Eli Lilly’s triple agonist may become the first obesity drug with dual indications

Eli Lilly and Company has announced successful topline results from its Phase 3 TRIUMPH-4 clinical trial evaluating retatrutide, a triple hormone receptor agonist, in adults with obesity and knee osteoarthritis. The once-weekly investigational therapy delivered significant dual benefits: an average weight loss of 28.7 percent and a 75.8 percent reduction in joint pain, measured by

Read More